Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis.

AIMS Platelet activation may be a determinant of thrombotic and restenotic complications following intracoronary stenting. In order to measure the effect of stenting on platelet activation antigen expression we used whole blood flow cytometry in 18 patients undergoing Palmaz-Schatz stenting (treated with full anticoagulation) and compared these with a group of 18 patients undergoing elective angioplasty. The effects of low molecular weight heparin and unfractionated heparin on platelet behaviour were also studied, both in vitro and in vivo to determine the contribution of prolonged heparin therapy to platelet activation following stenting. METHODS AND RESULTS Fibrinogen binding to activated GPIIb-IIIa, and surface expression of P-selectin, GPIb and GPIIb-IIIa antigens were measured in unstimulated peripheral blood samples (rest) and on stimulation with adenosine diphosphate (0.1-10 micromol x 1(-1)) and thrombin (0.02-0.16 U x ml(-1)). No changes were seen in resting samples following angioplasty or stenting. Agonist responsiveness was unaltered after angioplasty, but in stented patients antigen expression in response to thrombin was significantly reduced (P< or =0.04), whilst the adenosine diphosphate response was significantly increased (P=0.01). Similar effects were observed in patients with unstable angina treated with either low molecular weight heparin or unfractionated heparin in vivo. In vitro, both unfractionated and low molecular weight heparin inhibited thrombin-induced platelet activation, but stimulation of adenosine diphosphate responses was more marked with unfractionated than low molecular weight heparin. CONCLUSIONS There was a significant increase in platelet responsiveness to adenosine diphosphate following intracoronary stenting in patients treated with conventional anticoagulants. This was probably a consequence of treatment with heparin. Activation of platelets by heparin may explain the increased rate of stent thrombosis in patients treated with anticoagulant therapy. Low molecular weight heparins stimulate platelets less than unfractionated heparin.

[1]  F. Gries,et al.  PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) , 1996, European heart journal.

[2]  H. Rupprecht,et al.  Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. , 1996, European heart journal.

[3]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[4]  J. Loscalzo,et al.  Heparin reverses the antiplatelet effect of nitric oxide , 1996 .

[5]  F. Neumann,et al.  Platelet function in acute myocardial infarction treated with direct angioplasty. , 1996, Circulation.

[6]  P. Kyle,et al.  Flow Cytometric Detection of Activated Platelets in Pregnant Women Prior to the Development of Pre-Eclampsia , 1995, Thrombosis and Haemostasis.

[7]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[8]  S. Moncada,et al.  Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty , 1994, The Lancet.

[9]  P. Hjemdahl,et al.  Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[10]  A. Goodall,et al.  Profound Platelet Degranulation Is an Important Side Effect of Some Types of Contrast Media Used in Interventional Cardiology , 1993, Circulation.

[11]  A. Goodall,et al.  Evaluation of Whole Blood Flow Cytometric Detection of Platelet Bound Fibrinogen on Normal Subjects and Patients with Activated Platelets , 1993, Thrombosis and Haemostasis.

[12]  A. Michelson,et al.  Effect of Strenuous Exercise on Platelet Activation State and Reactivit , 1993, Circulation.

[13]  B. Pasche,et al.  The platelet function defect of cardiopulmonary bypass. , 1993, Blood.

[14]  P. Mannucci,et al.  Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  P. Teirstein,et al.  Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  J. Soria,et al.  Effect of heparin and enoxaparin on platelet interaction with fibrin clots. , 1992, Thrombosis research.

[17]  C. Abrams,et al.  Immunological Detection of Activated Platelets in Clinical Disorders , 1991, Thrombosis and Haemostasis.

[18]  P. Serruys,et al.  Stenting of coronary arteries: has a modern Pandora's box been opened? , 1991, Journal of the American College of Cardiology.

[19]  A. Goodall.  Platelet activation during preparation and storage of concentrates: detection by flow cytometry. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  R. McEver.  GMP‐140: A receptor for neutrophils and monocytes on activated platelets and endothelium , 1991, Journal of cellular biochemistry.

[21]  B Meier,et al.  Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.

[22]  T. Warkentin,et al.  Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation , 1990, British journal of haematology.

[23]  M. Horne,et al.  The effect of molecular weight on heparin binding to platelets , 1990, British journal of haematology.

[24]  D. Mikhailidis,et al.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). , 1987, British journal of clinical pharmacology.

[25]  J. Hoxie,et al.  Detection of activated platelets in whole blood using activation- dependent monoclonal antibodies and flow cytometry , 1987 .

[26]  J. Goding,et al.  Monoclonal Antibodies: Principles and Practice , 1996 .

[27]  G. Bratt,et al.  Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. , 1986, Thrombosis research.

[28]  J. Westwick,et al.  Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. , 1986, Thrombosis Research.

[29]  L. Brace,et al.  Heparin-induced platelet aggregation is inhibited by antagonists of the thromboxane pathway. , 1985, Thrombosis research.

[30]  L. Brace,et al.  An Objective Assessment of the Interaction of Heparin and Its Fractions with Human Platelets , 1985, Seminars in thrombosis and hemostasis.

[31]  S. Mohammad,et al.  Effects of heparin on platelet aggregation and release and thromboxane A2 production. , 1981, The American journal of pathology.

[32]  D. Macintyre,et al.  Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation. , 1981, Thrombosis research.

[33]  J. Joist,et al.  Role of platelet-prostaglandin synthesis in shear-induced platelet alterations. , 1980, Blood.

[34]  U. Lindahl,et al.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. , 1980, Thrombosis research.

[35]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.

[36]  B. Weksler,et al.  Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation. , 1979, Thrombosis research.

[37]  C. Eika.  Platelet refractory state induced by heparin. , 2009 .